Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

“…Mutation of seven residues to A (I118A, L122A, F125A, Q126A, L232A, I235A, and L239A) markedly decreased the F3-induced inhibition of TASK-1 channels, consistent with the molecular modeling predictions. …”

Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

“…Mutation of seven residues to A (I118A, L122A, F125A, Q126A, L232A, I235A, and L239A) markedly decreased the F3-induced inhibition of TASK-1 channels, consistent with the molecular modeling predictions. …”

Supplementary Material for: Platelet Decreases following Continuous Renal Replacement Therapy Initiation as a Novel Risk Factor for Renal Nonrecovery by Griffin B.R. (8570007)

“…Primary predictors were platelet nadir discretized by median value and percent platelet decrease following CRRT initiation, with cut points evaluated by decile from 30 to 60%. …”

Table_1_Decreasing the carbon footprint of food through public procurement—A case study from the municipality of Härnösand.XLSX by Mari Kjellberg (20130183)

“…This study examines alternative purchase processes that may decrease the carbon footprint of publicly procured food through a case study of a municipality in the Northern part of Sweden. …”

K562 cells were treated with 40 nM of miR-214 mimics or a negative mimics control for 24 h, followed by treatment with 50 μM of hemin for 48 h. by Tipparat Penglong (164413)

Atomically Precise Au₄₂ Nanorods with Longitudinal Excitons for an Intense Photothermal Effect by Yingwei Li (701628)

Subjects:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

Melting points of HNL1 (A & B) and <i>Hb</i>HNL (C & D). by Bryan J. Jones (7354394)

“…<p>Melting points were measured by decreases in fluorescence intensity (A & C) and by decreases in fluorescence lifetime (B & D). …”

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Decreased number of cones and retinal ganglion cells in Oc-deficient retina. by Michaela Kreplova (9239560)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

siRNA Knockdown of PKCδ decreases phosphorylation of VEEV capsid. by Brian D. Carey (6092747)

Hematopoietic-restricted loss of Zeb1 decreases hematopoietic colony formation potential and ability to compete with wt HSPCs for contribution to all hematopoietic lineages. by Jueqiong Wang (11467505)

Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? by Isa Sincer (7234577)

“…<div><p>Abstract Background: Coronary artery fistula (CAF) is an abnormal connection that links a coronary artery to a cardiac chamber or another major blood vessel. …”